Place des nouveaux anticoagulants oraux en salle de cardiologie interventionnelle

Connolly, 2009, RE-LY steering committee and investigators. Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Patel, 2011, Rivaroxaban versus warfarin in non-valvular atrial fibrillation, N Eng J Med, 365, 883, 10.1056/NEJMoa1009638 Legrand, 2001, The use of dabigatran in elderly patients, Arch Intern Med, 171, 1285, 10.1001/archinternmed.2011.314 Stangier, 2010, Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran exilate: an open-label, parallel-group, single-center study, Clin Pharmacokinet, 49, 259, 10.2165/11318170-000000000-00000 Eerenberg, 2011, Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects, Circulation, 124, 1573, 10.1161/CIRCULATIONAHA.111.029017 Cotton, 2011, Acutely injured patients on dabigatran, N Eng J Med, 365, 2039, 10.1056/NEJMc1111095 Marlu, 2012, Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomized crossover ex-vivo study in healthy volunteers, Thromb Haemost, 108, 217, 10.1160/TH12-03-0179 Levi, 2012, Reverse engineering for new oral anticoagulants: non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban, Thromb Haemost, 108, 201, 10.1160/TH12-05-0330 Les nouveaux anticoagulants oraux (dabigatran et rivaroxaban) dans la fibrillation auriculaire: ce qu’il faut savoir. Point d’information Afssaps du 26 avril 2012. Gibson CM. ATLAS ACS-TIMI 51. Session Late-Breaking Clinical Trial I. Congrès de l’American College of Cardiology, 13 novembre 2011. Mega, 2012, Rivaroxaban in patients with a recent acute coronary syndrome, N Engl J Med, 366, 9, 10.1056/NEJMoa1112277